☆ 4.5 Article

Long-term outcomes of an advanced hybrid closed-loop system: A focus on different subpopulations

DIABETES RESEARCH AND CLINICAL PRACTICE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Endocrinology & Metabolism

Hybrid closed Loop improved glucose control compared to sensor-augmented pumps in outpatients with type 1 diabetes in real-life conditions with telehealth monitoring

C. Thivolet et al.

Summary: The study showed that initiation of insulin pump therapy for outpatients is safe and telehealth monitoring after outpatient initiation can help improve glucose control. Hybrid Closed Loop systems are compatible with outpatient pump initiation and provide the largest improvements in glucose control.

ACTA DIABETOLOGICA (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes

Anders L. Carlson et al.

Summary: This trial assessed the safety and effectiveness of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. The results demonstrate that this system is safe and allows patients to achieve recommended glycemic targets, with the potential to further optimize glycemia.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece

Vaia Lambadiari et al.

Summary: This study compared the cost-effectiveness of the Advanced Hybrid Closed Loop MiniMed 780G (AHCL) system versus sensor augmented pump (SAP) system with predictive low glucose management (PLGM) or multiple daily injections (MDI) plus intermittently scanned continuous glucose monitoring (isCGM) in people with type 1 diabetes in Greece. The study found that the MiniMed 780G system is likely to be cost saving compared with the SAP plus PLGM system and cost-effective compared with MDI plus isCGM, providing increased quality-adjusted life expectancy for patients.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial

Benjamin J. Wheeler et al.

Summary: The data suggests that automated insulin delivery (AHCL) has the potential to increase treatment satisfaction and improve subjective sleep quality in adolescents and adults with T1D compared to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM).

ACTA DIABETOLOGICA (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users

Julien Da Silva et al.

Summary: The preliminary performance evaluation of the MiniMed 780G system in real-world settings shows that most users are able to achieve good glycemic control and minimize hypoglycemia, indicating the effectiveness of the system.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus

Basilio Pintaudi et al.

Summary: This study evaluated the effectiveness of the Minimed 780G system in patients with type 1 diabetes. The results showed that the system significantly improved glucose control and reduced the risk of hypoglycemia and glucose variability.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI)

Goran Petrovski et al.

Summary: The study evaluated the glycemic outcomes in children and adolescents with Type 1 Diabetes (T1D) who were previously treated with Multiple Daily Injections (MDI) using a structured initiation protocol for the Advanced Hybrid Closed Loop (AHCL) Minimed 780G insulin pump system. The results showed that following a 10-day training, the participants achieved the internationally recommended goals of glycemic control with a time in range (TIR) above 70% and a HbA1c below 7%.

BMC ENDOCRINE DISORDERS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control

Giuseppe Lepore et al.

Summary: This study retrospectively evaluated the effect of switching to an AHCL system on metabolic control in adult patients with type 1 diabetes. The results showed that all four treatment groups achieved improved glycemic control two months and six months after the switch, meeting the recommended targets by the ADA.

ACTA DIABETOLOGICA (2022)

添加到收藏夹

Article Medicine, General & Internal

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial

Richard M Bergenstal et al.

LANCET (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes

Olivia J. Collyns et al.

Summary: The study found that the MiniMed Advanced Hybrid Closed-Loop (AHCL) system significantly improved glucose control in participants with type 1 diabetes, especially during the night. All age groups showed improvements, with adolescents showing the most significant improvement.

DIABETES CARE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology

Marc D. Breton et al.

Summary: In a real-world analysis of Control-IQ technology users, the study found that the technology demonstrated good glycemic improvements in different types of diabetes patients. Over the 12-month observation period, the level of time spent in automation remained high, and the time within the blood glucose control target range also increased.

DIABETES TECHNOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes

Pilar Isabel Beato-Vibora et al.

Summary: The study aimed to evaluate the impact of AHCL system implementation on glycemic control in patients with type 1 diabetes. Results showed that after using the AHCL system, patients had significantly increased TIR, reduced time in hyperglycemia, and no significant change in hypoglycemia time.

DIABETES TECHNOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden

Johan Jendle et al.

Summary: Using the IQVIA CORE Diabetes Model (v9.0), the study evaluated the long-term cost-effectiveness of the MiniMed 780G system versus isCGM plus MDI or CSII in T1D patients. Results showed that the MiniMed 780G system had significant improvements in life expectancy and quality-adjusted life expectancy compared to isCGM plus MDI or CSII.

DIABETES THERAPY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting

Pilar Isabel Beato-Vibora et al.

Summary: After 3 months of using the Medtronic 780G Advanced Hybrid Closed-Loop (AHCL) system, the time in range (TIR) for blood glucose levels between 70-180 mg/dl increased from 67.3% to 80.1%, with reduced risk of hypoglycemia. Patient satisfaction with the system also improved.

DIABETES RESEARCH AND CLINICAL PRACTICE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives

Korey K. Hood et al.

Summary: In comparison to first generation HCL, the use of Medtronic AHCL significantly improved glucose monitoring satisfaction, which was associated with glycemic improvements, while other PROs showed no significant differences.

DIABETES TECHNOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Engineering, Biomedical

MiniMedTM780G Insulin pump system with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacy

Jennifer McVean et al.

Summary: The MiniMed™ 780 G as a second-generation advanced hybrid closed-loop system has shown promising clinical and safety outcomes in initial pivotal trials. Real-world data and longer-term studies are still needed to further validate its effectiveness. The success of AID devices in the future depends on their ease of use and ability to reduce the burden of living with T1D.

EXPERT REVIEW OF MEDICAL DEVICES (2021)

添加到收藏夹

Review Engineering, Biomedical

Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations

M. Eleonora Aiello et al.

Summary: This review highlights the safety and effectiveness of automated insulin delivery systems in individuals with type 1 diabetes, as well as the challenges and requirements for improving these systems for different subpopulations. Recent advances in clinical studies are also discussed.

CURRENT OPINION IN BIOMEDICAL ENGINEERING (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino et al.

DIABETES CARE (2019)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.